Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London
Globe Newswire•04/11/2026•08:00 ET
0
Key Highlights
- ➤Electra Therapeutics (ETRA) will present at Jefferies Global Healthcare Conference November 18, 2026
- ➤Ipsoprubart is in a global registrational program for secondary hemophagocytic lymphohistiocytosis
- ➤Ipsoprubart is being evaluated in a Phase 1 trial for relapsed/refractory T-cell malignancies
- ➤ELA822 is being developed for chronic T cell-mediated immune and inflammatory diseases
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc. (NASDAQ: ETRA) a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced that management will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026 at 1:00 p.m. GMT.
A live webcast of the presentation will be available in the Investors section of Electra’s website at ir.electra-therapeutics.com and a replay will be available following the event.
Get started
Create a free account to read the full story.